

Belgian economic mission

Academic event on 17 June 2024

“Introduction to key actors and activities in the Oslo Science City Innovation District”

1. Practical information

Date and time: Monday 17 June, 14.00 – 14.55

Venue: Oslo Science Park, meeting room Lyng, Gaustadalléen 21, 0349 Oslo

Participants: Academic and economic delegations

Lead: Oslo Science City in collaboration with UCLouvain, University of Oslo and WB Campus

2. Programme

Welcome to Oslo Science City – Norway’s first innovation district

Carl Henrik Gørbitz, Director UiO: Life Science

Health and Life Science – a gravitational field of excellence in Oslo Science City

Jan Bjålie, Dean of Research and Innovation, Faculty of Medicine, University of Oslo

The rapidly evolving therapeutic nuclear medicine area of cancer

Øyvind Bruland, Professor of Clinical Oncology, Faculty of Medicine, University of Oslo

Building an ecosystem for collaboration and value creation

- Caroline Stokke, Associate Professor – Biophysics and Computational Radiology, Oslo University Hospital
- Thomas Birger Eden-Jensen, Head of Product Supply Operations, Bayer AS
- Erik Flatmark, CEO Agilera Pharma

In conversation facilitated by:

- Leif Rune Skymoene, CEO Association of the Pharmaceutical Industry in Norway (LMI)

Closing remarks

- Øyvind Bruland, Professor of Clinical Oncology, Faculty of Medicine, University of Oslo
 - Leif Rune Skymoene, CEO Association of the Pharmaceutical Industry in Norway (LMI)
-

3. Description

A presentation of different stakeholders in the innovation district will be held by Carl Henrik Gørbitz, CEO of UiO: Life Science, with an emphasis on life sciences and nuclear medicine. The introduction will be followed by a thematic session on Excellence in nuclear medicine.

4. Speakers' biographies



Carl Henrik Gørbitz, Director UiO: Life Science

Carl Henrik Gørbitz is since 2018 the Director of UiO:Life Science, a strategic initiative aiming to initiate and support interdisciplinary life science research, innovation, and education at the University of Oslo. Gørbitz is a professor of chemistry, with research activities focused on the solid-state properties of organic molecules, mainly amino acids and peptides, but also various other bioactive substances. He served as the head of education at the Department of Chemistry for many years and has a keen interest in teaching and learning methodologies.

Gørbitz is the host of Norway Life Science, the largest conference of its kind in Norway, sits in the board of Centre for Philosophy and the Sciences (CPS) and is member of the strategic council of The Life Science Cluster (TLSC).




Jan Bjaalie, Dean of Research and Innovation at the Faculty of Medicine, University of Oslo

MD PhD, is Dean of Research and Innovation at the Faculty of Medicine, University of Oslo since 2023. He is professor of anatomy and neuroscience at the Institute of Basic Medical Sciences, University of Oslo, Head of the Norwegian Neuroinformatics Node, and leader of the Data services of the EBRAINS Research Infrastructure.

He served as Head of the Institute of Basic Medical Sciences, University of Oslo (2009-2016), founding Executive Director of the International Neuroinformatics Coordinating Facility (INCF) at Karolinska Institute (2006-2008), Chair of the INCF Governing Board (2013-2016), and co-Chair of the International Brain Initiative (2019 - 2020). In the EU flagship Human Brain Project, he has been Neuroinformatics Platform leader (2017 – 2020) and Infrastructure Director (2018 - 2022).

His research group has studied sensory map transformations and wiring patterns in the brain and developed data systems for organizing and managing neuroscience research data with the use of a new generation of digital brain atlases.

Jan Bjaalie is Chief editor of Frontiers in Neuroinformatics and former Section editor of Brain Structure and Function.



Øyvind Bruland, Professor of Clinical Oncology, Department of Medical Oncology & Radiotherapy, The Norwegian Radium Hospital

Øyvind S Bruland (MD, PhD, BSc) is a certified radiation- and medical oncologist with special scientific interest and clinical experience in sarcomas and skeletal metastases. Since 2008 he has held the Tenure position as Professor of Clinical Oncology, University of Oslo, Norway, since January 2023 as Professor emeritus. Employed at the Norwegian Radium Hospital since 1983 where he did his PhD in tumorbiology. Since 1996 senior consultant oncologist, Dept. of Oncology,

Norwegian Radium Hospital, Norway.

In 2008, he was elected member of The Norwegian Academy of Science and Letters – Det Norske Videnskaps-Akademi.

He is a serial entrepreneur in the field of novel therapeutic radiopharmaceuticals and co-founders of Algeta ASA, Nordic Nanovector ASA, Oncoinvent AS and ArtBio AS.

In 2014 he was granted “The Innovation Price”, University of Oslo; shared with his co-inventor Roy H.Larsen.



Caroline Stokke, Assoc. Prof, MPE - Head of Nuclear Medicine & PET Physics, Head of Research group Theragnostic Imaging, Division of Radiology and Nuclear Medicine, Oslo University Hospital

Assoc prof II, University of Oslo

Caroline Stokke has been Head of the nuclear medicine physics section at Oslo University Hospital since 2013. She established a new research group at the hospital in 2017, entitled “Theragnostic Imaging”, for which she is still group leader. Dr. Stokke is also associate professor at the University of Oslo. Over the last decade, she has worked with a wide range of different radiopharmaceuticals and been actively involved in both research activities and clinical implementation. Her research group is mainly focussed on dosimetry and novel radiotherapeutics.

Dr. Stokke is involved in several international organisations, e.g. as chair of the European Association of Nuclear Medicine’s dosimetry committee and member of the executive board of EURAMED. Stokke is also associate editor in EJNMMI Physics. She currently serves as president of the Norwegian Association for Medical Physics.



Thomas Birger Eden-Jensen, Head of Product Supply Operations, Bayer AS

As a seasoned manufacturing and supply chain professional with a passion for radiopharmaceuticals, I’ve spent over a decade optimizing operations and driving efficiency.

My journey began in the pharmaceutical industry, where I honed my skills in process development, technology transfer, Operation Excellence/LEAN and

management. From there, I transitioned to radiopharmaceuticals, fascinated by their critical role in diagnostics and treatment, with focus on Clinical and Commercial production, and supply chain operations and CDMO oversight.

Led cross-functional teams in streamlining manufacturing and supply chains for life-saving and -improving isotopes. Implemented data-driven strategies to reduce lead times and enhance product availability, as well as issue management and debottlenecking. Collaborated with regulatory bodies to ensure compliance and safety.



Erik Flatmark, CEO Agilera Pharma

Erik Flatmark is the CEO of Agilera Pharma, an internationally leading development and manufacturing company within therapeutic radiopharmaceuticals for the use in cancer patients. Agilera is a 100% owned subsidiary of Institute for Energy Technology, located in the Oslo "cluster of expertise" within radiopharmaceuticals, and was established to capture the high growth in this truly exciting area of medicine.

Flatmark is a pharmacist by training and has been working in the pharma industry for more than 35 years. His career includes international roles at Bayer, located in a.o. Germany and in Asia, in addition to many years working with early phase companies, predominantly within the pharma CDMO space (contract development and manufacturing).



Leif Rune Skymoene, CEO LMI

Leif Rune Skymoene holds a Cand.pharm. degree from the University of Oslo with a year of graduate studies at the University of Oxford, as well as an Executive Master of Management from BI.

He began his career in the pharmaceutical industry in 2002 as a pharmaceutical consultant at Eli Lilly. There, he progressed through the ranks in the Norwegian and European organizations, eventually becoming the top executive in Norway.

In 2013, he transitioned to the organizational sector, serving as the leader of the Nansen Neuroscience Network.

In 2015, he returned to the pharmaceutical industry as an industrial builder at Curida. Skymoene was instrumental in founding Curida, starting from the Takeda Nycomed factory in Elverum. Today, they have 190 employees across four production facilities in Norway.

He assumed the role of CEO at LMI on March 1st. last year.

5. Participants

Norwegian delegation

1. Marianne Knarud, UiO
2. Siri, Aanstad, UiO
3. Hilde Nebb, UiO Growth House
4. Norunn Torheim, UiO Growth House, University of Oslo
5. Jonas Vårum Olafsen, Acting Head of Business Development, Municipality of Lillestrøm
6. Tor Paulson, Høgskolen i Innlandet
7. Haugen Håvard J, University of Oslo
8. Crina Damsa, University of Oslo
9. Beate Rygg Johnsen, UiO Growth House
10. Per Morten Sandset, UiO
11. Hanne Flinstad Harbo, Dean, Faculty of Medicine, UiO
12. Youness Azimzade, UiO
13. Birte Hansen, UiO/ dScience
14. Grete Dyb, University of Oslo, Faculty of Medicine
15. Elisabeth Authen Sethre, University of Oslo
16. Caspar Philip Price Hafslund, UiO
17. Carl Henrik Gørbitz, UiO
18. Markus Bugge, University of Oslo / TIK Centre for Technology, Innovation and Culture
19. Charlotte Claeysen, Oslo University
20. Katrine Vetlesen, Oslo Science City
21. Åse-Marit Kristiansen, University of Oslo
22. Janne Reseland, OD/UiO
23. Ingrid Sogner, University of Oslo
24. Yasir Islam, Education

Official delegation

1. Mrs Aline FRANCHIMONT, Project Manager, WALLONIE-BRUXELLES CAMPUS (WB CAMPUS)
2. Mrs Annelies GORISSEN, Manager Energy and Circular Economy POM Limburg, PROVINCIALE ONTWIKKELINGSMAATSCHAPPIJ LIMBURG

Business delegation

1. Mrs Samia BOUHJAR, Founder, ONAMYA
2. Mr Wim DE SCHACHT, Director, Vice-President, DAIKIN EUROPE
3. Mrs Frieda DEPAMELAERE, CEO, LINGUITEX
4. Mr Jens ISMAR, Executive Director Shipping, EXMAR MARINE
5. Mr Tom LAVEREN, Managing Director, VOKA - CHAMBER OF COMMERCE AND INDUSTRY - MECHELEN-KEMPEN

6. Mr Etienne LAUWERYS, Investment Manager, SFPIM-INTERNATIONAL
7. Mr Christoph PAUWELS, Managing Director, FRESH & SAUCY FOODS
8. Mr Denis RONDAY, General Adviser International Affairs, SFPIM-FPIM
9. Mr Mathieu RYCKEWAERT, Chief Sustainability & Governmental Affairs Officer, HERSTAL GROUP
10. Mr Koenraad VAN LOO, CEO, SFPIM-FPIM
11. Mr Hans VAN SOEST, Founding Partner & CEO, VISION3F
12. Mr Nick VERWIMP, CEO, NV PROJECTBOUW

Academic delegation

1. Mr Robert BAUDINET, CEO at Matvision and Research Engineer, GeMMe, UNIVERSITE DE LIEGE-ULG
2. Mrs Sandra BELBOOM, Lecturer, HAUTE ECOLE LIBRE MOSANE
3. Mr Valery BROUN, Head of the “science and technology” department, HAUTE ECOLE DE LA PROVINCE DE LIEGE-HEPL
4. Mrs Pauline CORNIL, Head of International Office, HAUTE ECOLE LOUVAIN EN HAINAUT
5. Mr Philippe DECLERCQ, Director-President, HAUTE ECOLE LOUVAIN EN HAINAUT-HELHA
6. Mr Jan HELSEN, Lead Performance and Diagnostics Monitoring OWI-Lab, VRIJE UNIVERSITEIT BRUSSEL
7. Mr Didier LAMBERT, Rector, UCLOUVAIN
8. Mrs Annick LAPIERRE, Director-President, HAUTE ECOLE DE LA PROVINCE DE LIEGE-HEPL
9. Mr Xavier LEPOT, Director of Research Administration, UCLOUVAIN
10. Mr Didier MATTIVI, Director of Research Innovation Support and Enterprises, UNIVERSITE DE LIEGE-ULG
11. Mr Robert MULLER, Director of International Partnerships, THE CENTER FOR MICROSCOPY AND MOLECULAR IMAGING (CMMI) - UMONS
12. Mrs Julie REMICHE, Director, HAUTE ECOLE DE LA PROVINCE DE LIEGE-HEPL
13. Mr Jean-Christophe RENAULD, Pro-Rector for Research, UCLOUVAIN
14. Mrs Dana SAMSON, Pro-Rector for International Affairs, UCLOUVAIN
15. Mr Luc SELS, Rector, KU LEUVEN
16. Mr Wouter SCHROEYERS, HASSELT UNIVERSITY
17. Mrs Christel VACELET, Director of the international office, UCLOUVAIN

Local delegation

1. Mr Dries WILLEMS, General Representative, DELEGATION OF FLANDERS IN THE NORDIC COUNTRIES
2. Mrs Lotte YSENBANDT, Deputy General Representative, DELEGATION OF FLANDERS IN THE NORDIC COUNTRIES